Visão geral da empresa
A commercial-stage medical technology enterprise, TELA Bio, Inc. specializes in delivering soft-tissue reconstruction solutions designed to optimize clinical outcomes through the preservation and restoration of patient anatomy. Operating within the healthcare sector and specifically the medical devices industry, the company focuses on providing a portfolio of OviTex Reinforced Tissue Matrix products to address complex tissue repair needs. The firm currently maintains a market capitalization of $28.47M and generated annual revenue of $80.28M, while the specific employee count is not disclosed in available records. These valuation and revenue figures indicate that the company operates with a modest market presence typical of a commercial-stage biotech firm that is still navigating the capital-intensive phases of product development and market penetration before achieving widespread profitability.
Saúde financeira
TELA Bio, Inc. reported a total revenue of $80.28M for the trailing twelve months, yet it recorded a net income loss of $38,831,000 and an EBITDA of $-32,745,000. The significant divergence between the $80.28M in revenue and the negative net income reveals a cost structure where operating expenses substantially exceed gross profits, a common characteristic in the early-to-mid stages of medical device commercialization. The company generated free cash flow of $-16,954,000, which indicates that cash outflows for capital expenditures and working capital needs currently exceed the cash generated from operations, limiting immediate financial flexibility for large-scale expansion without external financing. Margins reflect this structural challenge, with a gross margin of 68.2% suggesting efficient product costing, but an operating margin of -31.9% and a profit margin of -48.4% highlighting the heavy burden of overhead and sales expenses. On the balance sheet, the company holds $50.84M in cash against $57.65M in debt, resulting in a debt-to-equity ratio of 913.26, which characterizes a highly leveraged position rather than a conservative one. However, the current ratio stands at 4.21, indicating a robust short-term liquidity position where current assets significantly outweigh current liabilities, providing a buffer to service obligations despite the high debt load. Return metrics further illustrate the financial strain, with a return on equity of -223.4% and a return on assets of -25.1%, signaling that management has not yet generated positive returns on the capital deployed for the business.
Avaliação de valorização
Valuation metrics for TELA Bio, Inc. present a complex picture, with a forward P/E of -1.13 and a trailing P/E ratio listed as N/A due to the lack of positive earnings. The distinction between a negative forward P/E and an unavailable trailing P/E implies that analysts are pricing in future earnings potential based on projections rather than historical performance, as the current earnings trajectory remains negative. The price-to-book ratio is recorded at 4.48, indicating that the market values the company's equity at a significant premium over its net asset book value, reflecting high growth expectations or intangible asset value not fully captured on the balance sheet. Alternative valuation multiples show a price-to-sales ratio of 0.35 and an EV/EBITDA of -1.08, suggesting that investors are willing to pay for revenue growth at a fraction of sales, while the negative EV/EBITDA underscores the company's lack of current cash flow generation. Price action shows a 52-week high of $2.20 and a 52-week low of $0.50; without a specific current price provided in the facts, the company's trading position is bounded by this wide range, suggesting high volatility and potential for significant price discovery. The stock exhibits a beta of 0.99, meaning its price volatility relative to the broader market is approximately equal to the market average, moving in tandem with general market fluctuations without significant deviation.
Growth & Income
Revenue growth for the company stands at 18.2% year-over-year, demonstrating a strong top-line expansion in the medical device sector. Earnings growth is listed as N/A, which implies that the earnings per share are not currently growing in a traditional sense due to the net loss position, creating a scenario where revenue expansion precedes profitability rather than following it. As the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically reinvested into the business, though in this instance, cash is being consumed to fund operations and debt obligations. Consequently, the overall growth and income profile is defined by aggressive revenue expansion coupled with a complete absence of income distribution, positioning the asset purely for capital appreciation potential rather than yield generation.